US EditionJarvis: Finally, hope for Parkinson’s
- Japanese scientists led by Jun Takahashi implanted lab-grown brain cells into Parkinson's patients in a May 2025 clinical trial in Kyoto.
- The trial followed advances at WEHI identifying a molecule that blocks neuron death, plus rising Parkinson's prevalence and no current cures.
- Seven patients participated, with four improving motor function by 20%, brain scans showing dopamine increases up to 63.5%, and no major side effects.
- Jun Takahashi expressed that confirming symptom improvement in patients marks a major milestone, highlighting important progress in the treatment.
- These combined breakthroughs could lead to new therapies for Parkinson's and other neurodegenerative diseases that currently lack effective treatments.
35 Articles
35 Articles
Why is life-changing Parkinson’s treatment out of reach for Edmonton patients?
For patients with advanced Parkinson’s disease, current medication regimens often lose their effectiveness over time. This leads to increasingly debilitating “off” periods, characterized by uncontrolled movements (dyskinesia) and painful, involuntary muscle contractions (dystonia). The window of “on” time — when symptoms are controlled — shrinks, severely impacting quality of life.
A Simple Eye Exam Could Spot Parkinson’s Before It Strikes
New research reveals a retinal light test may hold the key to detecting Parkinson’s disease long before motor symptoms appear. Could your eyes reveal signs of Parkinson’s disease before symptoms appear? A new study says yes—and it might revolutionize early detection. Researchers from Université Laval, publishing in the journal Neurobiology of Disease, have found that [...]
Identifying brain-penetrant small-molecule modulators of human microglia using a cellular model of synaptic pruning
Microglia dysregulation is implicated across a range of neurodevelopmental and neurodegenerative disorders, making their modulation a promising therapeutic target. Using PBMC-derived induced microglia-like cells (piMGLCs) in a scalable assay, we screened 489 CNS-penetrant compounds for modulation of microglial phagocytosis of human synaptosomes in a validated assay for microglia-mediated synaptic pruning. Compounds from the library that reduced …
Coverage Details
Bias Distribution
- 54% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
